Business
Vaccine shows ‘promising’ response in published study, but more research needed – Sydney Morning Herald
Early results from the vaccine trial show that volunteers developed higher levels of virus-killing antibodies than people who had recovered from COVID-19.
Chicago: A COVID-19 vaccine developed by the biotechnology company Moderna in partnership with the US National Institutes of Health has induced immune responses in all 45 healthy volunteers who received it in a phase one study.
Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, whose researchers developed Moderna’s vaccine candidate, called the results “good news”, noting that the study found no serious adverse events and the vaccine produced “reasonably high” levels of virus-killing or neutralising antibodies.
“If your vaccine can induce a response comparable with natural infection, that’s a winner,” Fauci said in a telephone interview. “That’s why we’re very pleased by the results.”
Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, is hailing the early results for a trial vaccine. Credit:Bloomberg
Volunteers who got two doses of the vaccine had high levels of virus-killing antibodies that exceeded the average levels seen in people who had recovered from COVID-19, the research team reported.
-
General23 hours agoTasmanian boy left homeless due to child protection department’s ‘gross negligence’, family member says
-
General13 hours agoHuman remains located, police make arrest in search for Sunbury man Joshua Bishop
-
Business23 hours agoThe smartest ASX dividend stocks to buy with $1,000 right now
-
Noosa News20 hours agoTownsville remembers Jennifer Board, four years on from tragic death